Keywords: positive, new, data, merck, co, cozaar, findings
Positive new data for Merck & Co's Cozaar
Article | 07 June 2004
Findings published in the Journal of Human Hypertension suggest that treatment with Merck & Co's Cozaar (losartan) could prevent almost 17,500 people ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
